Thursday March 16, 2023
Neil Clark speaks to Endpoint – ‘UK biotech hands off mid-stage C. difficile...
Destiny Pharma’s CEO, Neil Clark, speaks to Endpoint. For the full article ‘UK biotech hands off mid-stage C. difficile drug in up to $570M deal’, please click here
Thursday March 16, 2023
Result of General Meeting and Total Voting Rights
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR […]
Wednesday March 15, 2023
Result of Open Offer
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR […]
Wednesday January 25, 2023
US Center for Disease Control review paper
Destiny Pharma plc (“Destiny Pharma” or the “Company”) US Center for Disease Control (CDC) and two major medical journals cite the importance of decolonization in preventing surgical site infections Brighton, […]
Thursday December 22, 2022